Developed with US respiratory specialist firm Innoviva, the drug (known as Breo Ellipta in the US) is GSK’s follow up to its respiratory blockbuster Advair/Seretide, but won’t come close to ...

With prices finalized for the first 10 Medicare ... process for the first time with their blockbusters, Trelegy Ellipta, Breo ...